1. Managerial evolution
 1997-1999: Junior Research Scientist (Cadre Technique), one technican.
 Development of [35S] GTPS binding at D3 receptors and demonstration of MAP kinase activation (western
blot) by D3 receptors involving an atypical PKC and the PI3-Kinase.
 Characterisation of S33084 and its tritiated radioligand, a highly selective and potent D3 receptor antagonist.
 Miniaturisation of binding protocols in 96 well format.
 1999-2001: Research Scientist (Cadre de Recherche), management of 2-4 technicians.
 Development of antibody capture assay as a measure of activation of specific G protein subtypes, employing
[35S] GTPS binding coupled to Scintillation Proximity Assay (SPA) detection at muscarinic receptors.
 Development of a new PLC activity assays at serotonin 5-HT2A/2B/2C receptors and at 1A adrenoceptors.
 Role of 2 adrenoceptors in actions of antiparkinson drugs. Antagonist action of piribedil at 2 adrenoceptors
coupled to MAP-kinase activation.
 Characterisation of pindolol and atypical antipsychotic agents at 5-HT1A receptors coupled to MAP-Kinase.
2001-2003: Group Leader (Chef d'Etudes Scientifiques), team with 5 people (one Ph D).
 Management of a team comprising one Ph.D., four technicians and one people in Master degree
 Management of drug screening programme and related database on 20 human and native rat G protein
coupled receptors and re-uptake sites expressed in different cell lines or tissues.
 Management of culture of 15 cell lines (CHO, IM9, U373-MG, SH-SY5Y…).
 Chronic studies in rat with several antidepressants: Impact on  adrenergic and 5-HT2A receptor level.
 Functional ([35S]GTPS) autoradiography by in situ detection of G protein activation on rat brain section.
 Studies of agonist-directed trafficking of signalling at dopamine (D1, D2S/2L, D3), serotonin (5 HT1A/1B, 5
HT2A/2B/2C), adrenergic (1A/1B, 2A) and muscarinic (M1, M4) receptors coupled to specific G proteins
(Gs, Gi3, Go, Gq) in cell lines and native rat tissues (hyppocampal, cortex, striatum), employing antibody
capture / SPA technology.
 ERK1/2 activation profiles of ligands at dopamine (D2L, D3), serotonin (5 HT1A, 5 HT2C), adrenergic (2A)
and tachykinin (NK1) receptors. Development of ERK1/2 activation by ELISA in 96 well format.
 Characterisation of affinity and efficacy of antiparkinson agents at 20 receptor subtypes
Listed information on published compounds at Servier
S16924 Potential 'atypical' antipsychotic agent with D2 and 5-HT1A receptor activities. Phase II (Discontinued).
S18327 Potential 'atypical' antipsychotic agent with D2 and 2 adrenoceptor activites. Phase I (Discontinued).
S33084 Potent and selective D3 receptor antagonist for treatment of schizophrenia. Pre-clinical research.
S33138 Dopamine D3 and D2 receptor antagonist for treatment of schizophrenia. Phase III (Discontinued).
S33592 Dopamine D2/D3 receptor low partial agonist: candidate for treatment of schizophrenia. Pre-clinical research.
S33005 Potent and selective SNRI with potential antidepressant properties. Pre-clinical research.
S35966 Potential antidepressant agent. Potent SNRI and antagonist at 2 adrenoceptors. Pre-clinical research.
S20098 VALDOXAN®
, launch in 2010. Antidepressant with dual melatonin 5-HT2C receptor properties.
S37245 Potential antidepressant/anxiolytic with partial agonist properties at 5-HT1A receptors. Pre-clinical research.
S32504 Selective dopamine D3 versus D2 agonist for Parkinson's disease or depression. Pre-clinical research.